Clinical characteristics and results of the patients performed immunohistochemistry
| Patient ID | S3 | S10 | Lip32 | Lip73 | Lip90 | S20 | Lip24 | Lip28 | Lip45 | Lip47 | Lip48 |
| Sex | Female | Female | Female | Female | Female | Female | Female | Female | Female | Female | Female |
| Age | 51 | 71 | 31 | 29 | 70 | 58 | 36 | 76 | 58 | 38 | 47 |
| Disease | sSS, MCTD | pSS | pSS | sSS, SSc | pSS | pSS | pSS | pSS | non-SS | non-SS | non-SS |
| ANA titre | >1:2560 | 1:640 | 1:640 | 1:2560 | 1:320 | 1:1280 | 1:640 | <1:40 | <1:40 | 1:40 | 1:80 |
| ANA type | s, c | h, d | h, d, n | d | h, c | s | s | h, s | h, s | ||
| Serum anti-SSA52/60 antibody | + | + | – | – | – | + | + | – | – | – | – |
| Serum anti-SSB antibody | + | – | – | – | – | + | + | – | – | – | – |
| Serum anti-CENP-B antibody | + | + | + | + | + | – | – | – | – | – | – |
| Serum rheumatoid factor | + | + | – | + | NA | + | + | – | NA | – | – |
| Greenspan grade | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 2 | 1 |
| Medication | PSL 10 mg/day | None | None | None | None | None | None | None | None | None | None |
| Tissue ASCs | |||||||||||
| Anti-GFP antibody* | – | – | – | – | – | – | – | – | – | – | – |
| Anti-MIS12C antibody* | +++ | +++ | +++ | +++ | +++ | – | – | – | – | – | – |
| Anti-CBX5 antibody* | – | – | ± | ± | – | – | – | – | – | – | – |
| Anti-CENP-A antibody* | ± | ± | + | ++ | ± | – | ± | ± | – | – | – |
| Anti-CENP-B antibody* | ± | ± | ± | + | – | – | – | – | – | – | – |
| Anti-CENP-C antibody* | +++ | +++ | ++ | +++ | ++ | – | – | – | – | – | – |
*Slides were examined at a magnification of ×200. -, undetectable; ±, one cell in multiple fields, +, 1–3 cells in one field; ++, 4–8 cells in one field; +++, >8 cells in one field.
c, cytosol; d, discrete-speckled; h, homogeneous; MCTD, mixed connective tissue disease; n, nucleolar; NA, not assessed; PSL, prednisolone; pSS, primary Sjögren's syndrome; s, speckled; SS, Sjögren's syndrome; sSS, secondary Sjögren's syndrome.